Comparison of the adjuvant effect of conbercept intravitreal injection at different times before vitrectomy for proliferative diabetic retinopathy
暂无分享,去创建一个
Junjie Ye | Y. Di | Zhi-kun Yang | Weihong Yu | Zijian Guo
[1] P. Xie,et al. Monitoring intraocular proangiogenic and profibrotic cytokines within 7 days after adjunctive anti‐vascular endothelial growth factor therapy for proliferative diabetic retinopathy , 2021, Acta ophthalmologica.
[2] P. Kaiser,et al. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study , 2021, British Journal of Ophthalmology.
[3] S. Chaudhary,et al. Proliferative diabetic retinopathy (PDR). , 2021, Disease-a-month : DM.
[4] G. H. Chen,et al. Intravitreal conbercept as an adjuvant in vitrectomy for proliferative diabetic retinopathy: a meta-analysis of randomised controlled trials , 2021, Eye.
[5] Xiaohong Gao,et al. Effect of intravitreal conbercept injection on VEGF-A and -B levels in the aqueous and vitreous humor of patients with proliferative diabetic retinopathy , 2021, Experimental and therapeutic medicine.
[6] You-xin Chen,et al. Perioperative anti-vascular endothelial growth factor agents treatment in patients undergoing vitrectomy for complicated proliferative diabetic retinopathy: a network meta-analysis , 2020, Scientific Reports.
[7] Jili Chen,et al. Intravitreal Conbercept Injection as an Adjuvant in Vitrectomy with Silicone Oil Infusion for Severe Proliferative Diabetic Retinopathy. , 2020, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[8] Junjie Ye,et al. Vascular endothelial growth factor concentration in vitreous humor of patients with severe proliferative diabetic retinopathy after intravitreal injection of conbercept as an adjunctive therapy for vitrectomy , 2020, Chinese medical journal.
[9] C. Faselis,et al. Microvascular complications of type 2 diabetes mellitus. , 2020, Current vascular pharmacology.
[10] G. Abbott. Detachment , 2018, Thucydides.
[11] B. Zheng,et al. Effect of intravitreal conbercept treatment before vitrectomy in proliferative diabetic retinopathy. , 2018, International journal of ophthalmology.
[12] S. Charles,et al. Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy , 2018, Journal of ophthalmology.
[13] E. Alimanović-Halilović,et al. Vitreous concentrations of vascular endothelial growth factor as a potential biomarker for postoperative complications following pars plana vitrectomy , 2018, Archives of medical science : AMS.
[14] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[15] Sloan W. Rush,et al. Preoperative Bevacizumab Administration in Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: A Randomized and Controlled Trial Comparing Interval Variation. , 2017, American journal of ophthalmology.
[16] H. Dong,et al. Comparison of effectiveness and safety between conbercept and ranibizumab for treatment of neovascular age-related macular degeneration. A retrospective case-controlled non-inferiority multiple center study , 2017, Eye.
[17] Xiaoling Liu,et al. EFFICACY AND SAFETY OF INTRAVITREAL CONBERCEPT INJECTIONS IN MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION , 2017, Retina.
[18] M. Humayun,et al. VISUAL AND ANATOMICAL OUTCOMES AFTER DIABETIC TRACTION AND TRACTION-RHEGMATOGENOUS RETINAL DETACHMENT REPAIR , 2017, Retina.
[19] Liangzhang Tan,et al. INTRAVITREAL CONBERCEPT (KH902) FOR SURGICAL TREATMENT OF SEVERE PROLIFERATIVE DIABETIC RETINOPATHY , 2016, Retina.
[20] Ting Zhang,et al. A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy , 2016, Journal of ophthalmology.
[21] D. Maberley,et al. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY: A Systematic Review and Meta-Analysis , 2015, Retina.
[22] Peizeng Yang,et al. Observation of total VEGF level in hyperglycemic mouse eyes after intravitreal injection of the novel anti-VEGF drug conbercept , 2015, Molecular vision.
[23] K. Eng,et al. A randomized study comparing the efficacy of bevacizumab and ranibizumab as pre-treatment for pars plana vitrectomy in proliferative diabetic retinopathy. , 2014, Ophthalmic surgery, lasers & imaging retina.
[24] X. Chen,et al. KH902 suppresses high glucose‐induced migration and sprouting of human retinal endothelial cells by blocking VEGF and PIGF , 2013, Diabetes, obesity & metabolism.
[25] H. Goto,et al. Intraocular VEGF level as a risk factor for postoperative complications after vitrectomy for proliferative diabetic retinopathy. , 2012, Investigative ophthalmology & visual science.
[26] Hong Li,et al. Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit. , 2012, Experimental eye research.
[27] T. Williamson,et al. Surgical and visual outcome following 20-gauge vitrectomy in proliferative diabetic retinopathy over a 10-year period, evidence for change in practice , 2012, Eye.
[28] J. Shaw,et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. , 2011, Diabetes research and clinical practice.
[29] K. Park,et al. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy. , 2011, Ophthalmology.
[30] Y. Mizutani,et al. DOSE OF INTRAVITREAL BEVACIZUMAB (AVASTIN) USED AS PREOPERATIVE ADJUNCT THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY , 2010, Retina.
[31] Z. Kapran,et al. TRANSCONJUNCTIVAL 25-GAUGE SUTURELESS VITRECTOMY AND SILICONE OIL INJECTION IN DIABETIC TRACTIONAL RETINAL DETACHMENT , 2008, Retina.
[32] S Von Hagen,et al. Epiretinal membrane removal in diabetic eyes: comparison of viscodissection with conventional methods of membrane peeling , 2003, The British journal of ophthalmology.
[33] P. Rothwell,et al. Meta-analysis of randomised controlled trials , 1997, The Lancet.
[34] Dahua Xu,et al. Pars plana vitrectomy assisted by intravitreal injection of conbercept enhances the therapeutic effect and quality of life in patients with severe proliferative diabetic retinopathy. , 2022, American journal of translational research.
[35] A. de Laat,et al. Network meta-analysis. , 2017, Journal of oral rehabilitation.